米国の生殖補助医療（ART）市場：製品別、技術別、患者タイプ別、エンドユーザー別、地域別、機会、予測、2018年～2032年

米国の生殖補助医療（ART）の市場規模は、2025年～2032年の予測期間中に5.40％のCAGRで拡大し、2024年の62億8,000万米ドルから2032年には95億6,000万米ドルに成長すると予測されています。同市場の成長は、親になる時期を遅らせることへの嗜好の高まり、ライフスタイルや食習慣の変化による不妊症の症例の増加、同市場で利用可能なさまざまな不妊治療法についての認知度の高まりが要因となっています。米国疾病予防管理センターの推計によると、15～49歳の女性の約13.4％が不妊症です。

米国では、同性カップルの増加やひとり親志向の高まりが、ARTへの依存をさらに高めています。卵子提供や精子バンクは第三者の生殖方法として受け入れられるようになり、妊娠代理出産は全米のいくつかの州で法的にも社会的にも受け入れられています。不妊治療クリニックは、多様な患者の要求に対応するため、ドナーバンクや代理出産マッチングサービスのネットワークを拡大しています。しかし、これらの取り決めには倫理的、法的な複雑さが伴うため、いくつかの課題があります。それにもかかわらず、患者とドナー双方の保護を確保するための標準化の枠組みにより、これらの分野における透明性は高まりつつあります。

当レポートでは、米国の生殖補助医療（ART）市場について調査し、市場の概要とともに、製品、技術別、患者タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 米国の生殖補助医療（ART）市場の見通し、2018年～2032年

• 市場規模分析と予測
• 市場シェア分析と予測
  • 製品別
    • 機器
    • 消耗品
    • 試薬と培地
  • 技術別
    • 体外受精（IVF）
    • 人工授精（AI-IUI）
    • 凍結胚移植（FER）
    • その他
  • 患者タイプ別
    • 男性
    • 女性
  • エンドユーザー別
    • 不妊治療クリニック
    • 病院
    • 外科センター
    • 臨床研究機関
    • その他
  • 地域別
    • 北東部
    • 中西部
    • 西部
    • 南部
  • 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
• 2024年の市場マップ分析

第6章 需要供給分析

第7章 輸出入の分析

第8章 バリューチェーン分析

第9章 ポーターのファイブフォース分析

第10章 PESTLE分析

第11章 価格分析

第12章 市場力学

• 市場の促進要因
• 市場の課題

第13章 市場動向と発展

第14章 規制枠組みとイノベーション

• 規制当局の承認

第15章 特許の情勢

第16章 ケーススタディ

第17章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要企業トップ10の情勢
  • CooperSurgical, Inc.
  • Thermo Fisher Scientific Inc.
  • FUJIFILM Irvine Scientific, Inc.
  • Cook Group Incorporated
  • Vitrolife, Inc.
  • Hamilton Thorne Inc.
  • Ferring B.V.
  • Genea Group
  • Esco Lifesciences Group Ltd.
  • Kitazato Corporation

第18章 戦略的提言

第19章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. United States Assisted Reproductive Technology (ART) Market, By Value, In USD Billion, 2018-2032F
• Figure 2. United States Assisted Reproductive Technology (ART) Market Share (%), By Product, 2018-2032F
• Figure 3. United States Assisted Reproductive Technology (ART) Market Share (%), By Technology, 2018-2032F
• Figure 4. United States Assisted Reproductive Technology (ART) Market Share (%), By Patient Type, 2018-2032F
• Figure 5. United States Assisted Reproductive Technology (ART) Market Share (%), By End-User, 2018-2032F
• Figure 6. United States Assisted Reproductive Technology (ART) Market Share (%), By Region, 2018-2032F
• Figure 7. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 8. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 9. By Patient Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 10. By End-User Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 11. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

United States assisted reproductive technology (ART) market is projected to witness a CAGR of 5.40% during the forecast period 2025-2032, growing from USD 6.28 billion in 2024 to USD 9.56 billion in 2032. The market's growth can be attributed to the increasing preference for delaying parenthood, rising cases of infertility due to changing lifestyle and eating habits and increasing awareness about the different fertility solutions available in the market. As per the estimates of the Center for Disease Control and Prevention, approximately 13.4% of women of ages 15-49 have impaired fertility.

The increasing number of same-sex couples, along with increasing preference for single parenthood in the United States, are further propelling the reliance on ART in the country. Egg donation and sperm banking have become accepted practices as third-party reproductive modes, and gestational surrogacy has gained legal and social acceptance in several states across the country. Fertility clinics are expanding their networks of donor banks and surrogate-matching services to accommodate the distinctive requirements of diverse patient populations. The ethical and legal intricacies associated with any of these arrangements, however, do present some challenges; nevertheless, transparency in these areas is on the rise due to the framework of standardization to ensure the protection of both patients and donors alike.

Increasing Investments Boost Market Growth

Investments in ART are enabling the expansion of fertility clinics, improving treatment accessibility, and advancements in medical technologies. Availability of capital supports research and development activities, resulting in higher success rates for artificial insemination and IVF, among other procedures. Additionally, investments also allow fertility clinics to modernize and expand their facilities, allowing them to provide high-quality care to the patient population.

In May 2023, Morgan Health (a JPMorgan Chase & Co. business unit) invested USD 25 million in Kindbody, a leading fertility clinic network, to expand the accessibility of high-quality reproductive healthcare services for employees across the United States to combat the growing threat of infertility.

Technological Advancements Support Market Expansion

Growing emphasis on technological innovations is driving the market's growth and bolstering the availability of technological solutions such as time-lapse embryo imaging, artificial intelligence-assisted embryo selection, non-invasive preimplantation genetic testing (niPGT), and advanced cryopreservation techniques. Artificial intelligence and machine learning tools are becoming increasingly useful in identifying the most viable embryos for implantation, thereby reducing cycle failure rates and improving live birth outcomes. Robot-assisted minimally invasive procedures make egg retrievals and embryo transfer more comfortable for patients and enable faster recovery. These technological improvements are making ART more accessible, efficient, and personalized, thus allowing the market players to expand their customer base.

Additionally, leading ART service providers are also focusing on collaborations to ensure the delivery of advanced technologies and services. For instance, in October 2024, Cryoport, Inc. partnered with TMRW Life Sciences, Inc. to provide fertility clinics with advanced solutions for secure transportation and management of the specimen.

Fertility Clinics Hold Major Market Share

Fertility clinics hold a major share of the market in the United States as they offer a broad range of fertility services, including fertility ART procedures, donor services, and counseling. The specialized workforce, state-of-the-art laboratories, and individual treatment protocols make clinics the preferred option for patients. Many clinics have cooperative agreements and are part of growing fertility networks supported by private equity firms, thus leading to greater consolidation and expansion. Such consolidation allows for greater service scalability, enhanced quality assurance, and regional and national brand marketing, allowing them to expand their market presence. Additionally, various fertility clinics are also focusing on developing digital patient portals, using mobile applications for tracking treatment adherence, and artificial intelligence-based cycle management platforms to make the treatment journey smoother, thus allowing the segment's expansion. Furthermore, various fertility clinics are also focusing on partnerships and collaborations to ensure the provision of advanced treatment solutions to the patient population.

For instance, in April 2024, First Fertility, one of the largest fertility networks in the United States, expanded its nationwide presence by partnering with Fertility & Surgical Associates of California (FSAC), a leading fertility practice known for advanced treatments. The collaboration aims to combine First Fertility's comprehensive, patient-centered care model with FSAC's expertise and advanced technology, enhancing access to state-of-the-art reproductive healthcare in the region.

Impact of the U.S. Tariffs on United States Assisted Reproductive Technology (ART) Market

The recently imposed tariffs have resulted in significant challenges for the ART market in the United States. The tariffs, aimed at boosting domestic manufacturing, have resulted in supply chain disruptions and increased costs for raw materials within the industry.

The tariffs are expected to bolster the costs of essential equipment and consumables for ART, including specialized laboratory equipment, cryopreservation media, and incubators. These increased costs are expected to cause hindrances for small and medium-sized fertility clinics that may struggle to absorb the increased expenses. Thus, affecting the affordability of the treatment solutions, limiting access to ART.

Key Players Landscape and Outlook

The market's key players are focusing on launching next-generation solutions to bolster the effectiveness of reproductive technologies. For instance, in July 2023, Thermo Fisher Scientific Inc. launched the Ion AmpliSeq Polyploidy Kit and the Ion ReproSeq PGT-A Kit for supporting preimplantation genetic testing-aneuploidy (PGT-A), commonly used to inform intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF) research. PGT-A testing is used to identify chromosomal abnormalities in embryos. Such launches are expected to enhance the probability of successful pregnancies and improve reproductive health outcomes for future generations by providing researchers with deeper genomic insights.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. United States Assisted Reproductive Technology (ART) Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Product
    • 5.2.1.1. Instruments
      • 5.2.1.1.1. Sperm Separators
      • 5.2.1.1.2. Embryo Incubators
      • 5.2.1.1.3. Cryosystems
      • 5.2.1.1.4. Other Instruments
    • 5.2.1.2. Consumables
      • 5.2.1.2.1. Culture Dishes and Plates
      • 5.2.1.2.2. Storage Vials
      • 5.2.1.2.3. Needles
      • 5.2.1.2.4. Embryo transfer Catheters
      • 5.2.1.2.5. Other Consumables
    • 5.2.1.3. Reagents and Media
      • 5.2.1.3.1. Embryo Culture Media
      • 5.2.1.3.2. Cryopreservation Media
      • 5.2.1.3.3. Semen Processing Media
  • 5.2.2. By Technology
    • 5.2.2.1. In-vitro Fertilization (IVF)
    • 5.2.2.2. Artificial Insemination (AI-IUI)
    • 5.2.2.3. Frozen Embryo Replacement (FER)
    • 5.2.2.4. Other Technologies
  • 5.2.3. By Patient Type
    • 5.2.3.1. Male
    • 5.2.3.2. Female
  • 5.2.4. By End-user
    • 5.2.4.1. Fertility Clinics
    • 5.2.4.2. Hospitals
    • 5.2.4.3. Surgical Centers
    • 5.2.4.4. Clinical Research Institutes
    • 5.2.4.5. Others
  • 5.2.5. By Region
    • 5.2.5.1. Northeast
    • 5.2.5.2. Midwest
    • 5.2.5.3. West
    • 5.2.5.4. South
  • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Product
  • 5.3.2. By Technology
  • 5.3.3. By Patient Type
  • 5.3.4. By End-user
  • 5.3.5. By Region

6. Demand Supply Analysis

7. Import and Export Analysis

8. Value Chain Analysis

9. Porter's Five Forces Analysis

10. PESTLE Analysis

11. Pricing Analysis

12. Market Dynamics

• 12.1. Market Drivers
• 12.2. Market Challenges

13. Market Trends and Developments

14. Regulatory Framework and Innovation

• 14.1. Regulatory Approvals

15. Patent Landscape

16. Case Studies

17. Competitive Landscape

• 17.1. Competition Matrix of Top 5 Market Leaders
• 17.2. SWOT Analysis for Top 5 Players
• 17.3. Key Players Landscape for Top 10 Market Players
  • 17.3.1. CooperSurgical, Inc.
    • 17.3.1.1. Company Details
    • 17.3.1.2. Key Management Personnel
    • 17.3.1.3. Products and Services
    • 17.3.1.4. Financials (As Reported)
    • 17.3.1.5. Key Market Focus and Geographical Presence
    • 17.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 17.3.2. Thermo Fisher Scientific Inc.
  • 17.3.3. FUJIFILM Irvine Scientific, Inc.
  • 17.3.4. Cook Group Incorporated
  • 17.3.5. Vitrolife, Inc.
  • 17.3.6. Hamilton Thorne Inc.
  • 17.3.7. Ferring B.V.
  • 17.3.8. Genea Group
  • 17.3.9. Esco Lifesciences Group Ltd.
  • 17.3.10. Kitazato Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

18. Strategic Recommendations

19. About Us and Disclaimer